RE: TTH - RBC.....
......."TTH included in today's Biotech Review of Small Cap to Mid Cap Companies.
Outperform target - $25."
You Betcha Polak.........Ms. Phillipa sure seems to like the results from the AZD-103 Human Trials and how they are proving to parallel the pre-clinical in every category. She also likes to extoll the virtues of such in-depth testing almost to the point that it's almost like shes never seen such extensive and compelling proof of concept and reproducability from of a drug. Shes come full circle from being rather hesitant to, it seems like, excited now that imo she understands what Elan and Transition have been doing here and the extent that Transition went to to ready it in the earlier stages before Elan beat out 10 other companys for the rights to it........
She sure sees the rapidly approaching AZD-103 Phasell's as the ultimate commitment by Elan to pick up the tab.........
.......I like the fact that she sees value in Transitions Drug Discovery Program coming down the road. That technology had over $200 million put into it to develop it and Dr. Cruz got it for a pittance.... https://www.bioscienceworld.ca/TheTransitionYear
GPP all.